-
ACE2, Diminazene Aceturate, and Sepsis Cardiomyopathy
2026-09-18
The February 2024 reference study identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and links pharmacological ACE2 activation with MasR–Sirt1-mediated mitochondrial biogenesis. Using DIZE and MLN-4760 in a mouse cecal ligation and puncture model, the authors connect ACE2 signaling with cardiac function, inflammation, oxidative stress, apoptosis, and mitochondrial regulation while emphasizing the preclinical status of the findings.
-
Angiotensin II, Ferroptosis, and NPC Radioresistance
2026-09-18
The reference study identifies a local angiotensin II–AGT–HIF-1α–HILPDA axis that suppresses ferroptosis and promotes radiotherapy resistance in nasopharyngeal carcinoma. Its integrated cell, molecular, animal, and tissue analyses support combined angiotensin receptor blockade and ferroptosis induction as a testable radiosensitization strategy, while also defining a rationale for investigating MAPK signaling as an upstream regulatory node.
-
EPZ5676: Selective DOT1L Inhibitor for Leukemia
2026-09-17
EPZ5676 is a potent and selective DOT1L inhibitor that blocks H3K79 methylation and suppresses MLL-fusion transcriptional programs. Its reported biochemical potency, cellular activity in MV4-11 cells, and xenograft responses support its use as a research tool for epigenetic leukemia studies, not as a clinical treatment.
-
Everolimus (RAD001) Cancer Assay Workflows
2026-09-17
Build more informative mTOR inhibition experiments with Everolimus (RAD001), combining pathway biomarkers, proliferation measurements, and apoptosis assays. The workflow separates growth arrest from cell killing so researchers can compare cancer models without overinterpreting a single viability endpoint.
-
Metabolism of Sumatriptan Revisited: CYP and MAO Routes
2026-09-16
Pöstges and Lehr re-examined sumatriptan biotransformation with recombinant human cytochrome P450 and monoamine oxidase enzymes, challenging the assumption that oxidative deamination is exclusively mediated by MAO A. Their HPLC-MS data identify parallel and sequential CYP-dependent N-demethylation routes, while confirming MAO A—but not MAO B—activity toward sumatriptan and its desmethyl metabolites.
-
Anti-ROR1 Antibody: Translational Workflow
2026-09-15
Build a rigorous ROR1 workflow spanning immobilized-protein binding, flow cytometry, and functional signaling studies with Zilovertamab. The article also shows how to use ROR1 measurements as a carefully bounded exploratory layer in deoxynivalenol liver-injury research without confusing an oncology reagent with evidence of a hepatic mechanism.
-
Cisplatin (CDDP) Cancer Research Workflows
2026-09-15
Build reproducible Cisplatin workflows for DNA damage, viability, apoptosis, and chemotherapy resistance studies. The guide translates a recent nasopharyngeal carcinoma study into practical assay choices while addressing formulation, timing, controls, and xenograft-readout challenges.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-14
Cy3 Goat Anti-Mouse IgG (H+L) Antibody is a Cy3-labeled secondary reagent for detecting mouse primary antibodies in immunofluorescence, flow cytometry, and western blot workflows. It should be qualified experimentally for each assay and is not presented as a diagnostic reagent or as a substitute for directly matched paper validation.
-
Pharmacological Chaperones Restore GABAA Proteostasis
2026-09-14
The reference study shows that several epilepsy-associated GABAA receptor α1 variants are loss-of-function defects linked primarily to impaired folding, assembly, trafficking, and degradation. It further identifies Hispidulin and TP003 as pharmacological chaperones that improve receptor surface expression and function in cellular models without inducing a detectable unfolded protein response.
-
GSK2606414 Workflow for ER Stress Research
2026-09-13
Build a time-resolved PERK assay that connects eIF2α signaling, translational control, and cell fate to practical ER stress research. This workflow also adapts the reference study’s progressive infection design to test how PERK activity may intersect with Nrf2-dependent redox defense without overstating the available evidence.
-
Perphenazine: From Receptor Pharmacology to Assay Design
2026-09-12
Perphenazine is a dopamine D2 receptor antagonist with a distinctive phenothiazine receptor profile. This article translates its neuropharmacology, mitochondria-mediated cell death induction, and emerging host-directed antibacterial evidence into practical assay-design decisions.
-
Neticonazole Hydrochloride Research Workflows
2026-09-12
Neticonazole Hydrochloride connects practical cutaneous candidiasis assays with an emerging colorectal cancer research use case. This guide covers fresh-solution preparation, microscopy, fungal susceptibility testing, exosome analysis, Bcl-2/Bax readouts, and troubleshooting without treating preclinical oncology findings as clinical evidence.
-
Epoxomicin: Selective Proteasome Inhibition
2026-09-11
Epoxomicin is a selective, irreversible proteasome inhibitor that covalently targets the 20S proteasome through its α',β'-epoxyketone group. Its 4 nM vendor-reported IC50 for chymotrypsin-like activity makes it useful for ubiquitin-proteasome pathway research, protein degradation assays, and proteostasis models.
-
Indole-3-pyruvic Acid: From Auxin to Translation
2026-09-11
Indole-3-pyruvic acid (IPA) is more than an auxin biosynthesis intermediate: it is a mechanistically informative tryptophan metabolite that connects plant hormone research, fungal genetics, and immune modulation via AhR. This thought-leadership guide shows how translational researchers can use IPA to design stronger pathway, pharmacology, and preclinical studies.
-
5-(N,N-dimethyl)-Amiloride in pH Research
2026-09-10
5-(N,N-dimethyl)-Amiloride hydrochloride is a mechanistic tool for separating Na+/H+ exchanger activity from endothelial inflammation, barrier failure, and cardiac ion dysregulation. This guide translates its isoform profile into practical workflows for intracellular pH regulation, sepsis-related endothelial injury, and ischemia-reperfusion studies.